Incyte Europe will be the base from which the company will conduct its European clinical development
US biopharmaceutical company Incyte is to establish the new headquarters of Incyte Europe in Geneva, Switzerland.
The Wilmington, Delaware headquartered company, which focuses on oncology R&D, will use Incyte Europe as the base from which it will conduct its European clinical development operations.
The company expects to occupy the 9,000ft2 facility by the middle of this year.
Hervé Hoppenot, President and CEO of Incyte, said establishing Incyte Europe in Geneva is 'a natural step in our company’s evolution'.
The company has a broad and growing pipeline of proprietary products, and this new facility in Europe 'will enable us to create the infrastructure needed to support our global drug development programmes', he added.